Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer
- PMID:28236981
- DOI: 10.1016/j.lungcan.2017.01.007
Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer
Abstract
Objectives: Unresectable stage III NSCLC (non-small cell lung cancer) confers a poor prognosis and interest is growing in the use of immunotherapy to improve outcomes for patients with this disease. We investigated the safety and efficacy of maintenance tecemotide, a mucin 1 (MUC1)-specific agent that induces T-cell responses to MUC1, versus placebo in Japanese patients with stage III unresectable NSCLC and no disease progression after primary chemoradiotherapy.
Materials and methods: Patients aged ≥20 years with unresectable stage III NSCLC, stable disease or clinical response after primary chemoradiotherapy and performance status ≤1, were recruited across 25 centers in Japan. Patients were randomized 2:1 to tecemotide (930μg as lipopeptide) or placebo subcutaneously once weekly for 8 weeks, then every 6 weeks until disease progression or treatment withdrawal. Cyclophosphamide 300mg/m2 (maximum dose 600mg) was given intravenously 3days before the first dose of tecemotide. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival, time to progression, time to treatment failure and safety.
Results: The intent-to-treat population comprised 172 patients; 114 received tecemotide and 58 placebo. Baseline characteristics were comparable between treatment arms. Most patients (94%) received primary concurrent chemoradiotherapy. There was no apparent trend toward increased OS time with tecemotide over placebo (median 32.4 versus 32.2 months, hazard ratio 0.95, 95% confidence interval 0.61-1.48; P=0.83). No improvements in secondary efficacy endpoints were observed. The frequency of treatment-related adverse events was similar, and serious adverse event rates were the same in both arms. There were no new safety signals.
Conclusions: These results do not support those from a randomized phase III study (START) of improved OS with tecemotide in the subgroup of patients treated with primary concurrent chemoradiotherapy.
Keywords: Immunotherapy; MUC1; Non-small cell lung cancer; Primary chemoradiotherapy; Tecemotide.
Copyright © 2017. Published by Elsevier B.V.
Similar articles
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team.Butts C, et al.Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.Lancet Oncol. 2014.PMID:24331154Clinical Trial.
- Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH.Patel JD, et al.Clin Lung Cancer. 2020 Nov;21(6):520-526. doi: 10.1016/j.cllc.2020.06.007. Epub 2020 Jun 12.Clin Lung Cancer. 2020.PMID:32807654Free PMC article.Clinical Trial.
- Tecemotide: an antigen-specific cancer immunotherapy.Wurz GT, Kao CJ, Wolf M, DeGregorio MW.Wurz GT, et al.Hum Vaccin Immunother. 2014;10(11):3383-93. doi: 10.4161/hv.29836.Hum Vaccin Immunother. 2014.PMID:25483673Free PMC article.Review.
- Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, Martín C, Ragulin Y, Zukin M, Helwig C, Falk M, Butts C, Shepherd FA.Mitchell P, et al.Ann Oncol. 2015 Jun;26(6):1134-1142. doi: 10.1093/annonc/mdv104. Epub 2015 Feb 26.Ann Oncol. 2015.PMID:25722382Clinical Trial.
- Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.Rajappa S, Sharma S, Prasad K.Rajappa S, et al.Adv Ther. 2019 Mar;36(3):563-578. doi: 10.1007/s12325-019-0876-4. Epub 2019 Jan 29.Adv Ther. 2019.PMID:30693419Review.
Cited by
- The expression of Nanog protein and fibroblast growth factor-inducible molecule 14 in patients with non-small cell lung cancer and their relationship with pathological characteristics and prognosis.Wang Y, Zhou P, Cui C, He X, Bian Y, Wang X.Wang Y, et al.Transl Cancer Res. 2021 May;10(5):2470-2477. doi: 10.21037/tcr-21-724.Transl Cancer Res. 2021.PMID:35116561Free PMC article.
- Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.Puri S, Shafique M, Gray JE.Puri S, et al.Curr Treat Options Oncol. 2018 Jun 21;19(8):39. doi: 10.1007/s11864-018-0556-7.Curr Treat Options Oncol. 2018.PMID:29931587Review.
- Comprehensive analysis of the mechanism and treatment significance of Mucins in lung cancer.Ning Y, Zheng H, Zhan Y, Liu S, Yang Y, Zang H, Luo J, Wen Q, Fan S.Ning Y, et al.J Exp Clin Cancer Res. 2020 Aug 17;39(1):162. doi: 10.1186/s13046-020-01662-3.J Exp Clin Cancer Res. 2020.PMID:32807223Free PMC article.Review.
- Current state of immunotherapy for non-small cell lung cancer.Malhotra J, Jabbour SK, Aisner J.Malhotra J, et al.Transl Lung Cancer Res. 2017 Apr;6(2):196-211. doi: 10.21037/tlcr.2017.03.01.Transl Lung Cancer Res. 2017.PMID:28529902Free PMC article.Review.
- Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.Zhu J, Li R, Tiselius E, Roudi R, Teghararian O, Suo C, Song H.Zhu J, et al.Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2.Cochrane Database Syst Rev. 2017.Update in:Cochrane Database Syst Rev. 2021 Dec 6;12:CD011300. doi: 10.1002/14651858.CD011300.pub3.PMID:29247502Free PMC article.Updated.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous